MedTrace Logo

Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder

NCT00216723 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2013-10-23

No results posted yet for this study

Summary

This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.

Conditions

Interventions

DRUG

Aripiprazole

The recommended starting and target dose for Abilify is 10 or 15mg/day administered on a once-a-day schedule without regard to meals. (Administer 10 to 30 mg/day according to the patient's condition)

Sponsors & Collaborators

  • Korea Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jieun Kwon · Korea Otsuka Pharmaceutical Co., Ltd.

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Completion
2009-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00216723 on ClinicalTrials.gov